Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

845 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R; SHARP Investigators. Baigent C, et al. Among authors: cass a. Lancet. 2011 Jun 25;377(9784):2181-92. doi: 10.1016/S0140-6736(11)60739-3. Epub 2011 Jun 12. Lancet. 2011. PMID: 21663949 Free PMC article. Clinical Trial.
Effects of lowering LDL cholesterol on progression of kidney disease.
Haynes R, Lewis D, Emberson J, Reith C, Agodoa L, Cass A, Craig JC, de Zeeuw D, Feldt-Rasmussen B, Fellström B, Levin A, Wheeler DC, Walker R, Herrington WG, Baigent C, Landray MJ; SHARP Collaborative Group; SHARP Collaborative Group. Haynes R, et al. Among authors: cass a. J Am Soc Nephrol. 2014 Aug;25(8):1825-33. doi: 10.1681/ASN.2013090965. Epub 2014 May 1. J Am Soc Nephrol. 2014. PMID: 24790178 Free PMC article. Clinical Trial.
Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst indigenous and non indigenous people at high cardiovascular risk.
Liu H, Patel A, Brown A, Eades S, Hayman N, Jan S, Ring I, Stewart G, Tonkin A, Weeramanthri T, Wade V, Rodgers A, Usherwood T, Neal B, Peiris D, Burke H, Reid C, Cass A; Kanyini Vascular Collaboration; Kanyini GAP Study Team. Liu H, et al. Among authors: cass a. BMC Public Health. 2010 Aug 5;10:458. doi: 10.1186/1471-2458-10-458. BMC Public Health. 2010. PMID: 20687931 Free PMC article. Clinical Trial.
Kidney disease: are you at risk?
Cass A. Cass A. Med J Aust. 2002 Jun 3;176(11):515-6. doi: 10.5694/j.1326-5377.2002.tb04545.x. Med J Aust. 2002. PMID: 12064979 No abstract available.
Determining Line of Therapy from Real-World Data in Non-Small Cell Lung Cancer.
Grady CB, Hwang WT, Reuss JE, Iams W, Cass A, Liu G, Patel D, Liu SV, Montenegro GLB, Patil T, Nieva JJ, Herrmann A, Marrone KA, Lam VK, Schwartzman W, Dowell J, Villaruz LC, Miller KL, Weiss J, Sun F, Velcheti V, Camidge DR, Aggarwal C, Sun L, Marmarelis ME. Grady CB, et al. Among authors: cass a. Pharmacoepidemiol Drug Saf. 2024 Dec;33(12):e70049. doi: 10.1002/pds.70049. Pharmacoepidemiol Drug Saf. 2024. PMID: 39586662 Free PMC article.
845 results